Sweden · Delayed Price · Currency is SEK Mendus AB Earnings Call Transcripts
Fiscal Year 2026
-
Clinical development advanced with the ADVANCE II trial reaching five-year survival and the CADENCE trial confirming safety and enrollment milestones. Financial discipline reduced costs and extended cash runway into Q1 2027. Multiple clinical readouts and U.S. expansion are planned, contingent on further financing.
-
Clinical programs in AML and CML advanced, with reduced costs and a strengthened cash position. Recruitment in key trials is ongoing, with interim results expected mid-year and a focus on broadening patient eligibility.
Fiscal Year 2025
-
Positive phase II data in AML and ovarian cancer support broad positioning of vididencel, with new CML trials planned for 2026. Financing secured extends runway into 2027, and strategic focus shifts to align with evolving AML and CML treatment landscapes.
-
Positive long-term survival data in AML supports broader clinical development, with key trials in AML, CML, and ovarian cancer advancing. Cash runway extends into early 2026, with staff reductions offsetting higher trial costs.
-
Positive Phase II AML and early ovarian cancer trial data support broad potential for vididencel, with key patent granted and late-stage development progressing. Cash burn decreased year-over-year, and first GMP batches are expected before year-end.
-
Supportive regulatory feedback and clinical progress in AML with Vididencel, ongoing expansion of trials, and strengthened leadership with a new CMO. Q1 2025 saw an operating loss of SEK 30 million and a cash position of SEK 84.7 million, with cash reserves expected to last into 2026.
Fiscal Year 2024
-
Updated survival data in AML and positive ovarian cancer trial results support further development of vididencel. Cash runway extends to early 2026, with phase III readiness as the main focus amid a challenging partnering environment.
-
Opened first clinical centers for the CADENCE trial and advanced pivotal readiness for vididencel in AML. Q3 net loss was SEK 23 million, with a cash position of SEK 109.3 million and extended runway. Key survival data from ADVANCE II will be presented at ASH.
-
Raised SEK 69 million, maintained a strong cash position, and advanced key clinical programs in AML, ovarian cancer, and soft tissue sarcoma. Proof of concept for vididencel in AML was confirmed, with pivotal trial preparations and major collaborations underway.